Option chain shows key data for BriaCell Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for BriaCell Therapeutics.

BriaCell Therapeutics (NASDAQ:BCTX) Stock, Option Chain

BriaCell Therapeutics

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Mountain,View,,Ca,,Usa,-,Feb,25,,2020:,The,Coursera

News

Pre-Market Outlook

Markets

Movers

AGMH

AZTR

BCTX

COUR

CPOP

GILD

GOOGL

INTC

JZXN

OMEX

PRPO

SHCO

TVRD

WEST

Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket

Computer,Screen,In,Hospital,Radiology,Room:,Beautiful,Multiethnic,Adult,Woman

Biotech

Health Care

Trading Ideas

General

BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in advanced breast cancer.

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

Display,Of,Stock,Market,Quotes

Earnings

AGRI

BTOG

ENPH

ETNB

FRGE

GAIA

GELS

MRIN

NDRA

NTHI

PEGA

SEDG

SNOA

SXTC

Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics Corp

Press Releases

BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

BriaCell Reports "Late-Breaker" Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Comments

BriaCell Therapeutics

BriaCell Therapeutics (BCTX) Options

Loading...

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell